The triad of erectile dysfunction, hypogonadism and the metabolic syndrome by Shabsigh, R et al.
The triad of erectile dysfunction, hypogonadism
and the metabolic syndrome
R. Shabsigh,
1 S. Arver,
2 K. S. Channer,
3 I. Eardley,
4 A. Fabbri,
5 L. Gooren,
6 A. Heufelder,
7 H. Jones,
8
S. Meryn,
9 M. Zitzmann
10
There has traditionally been a widely held belief that
testosterone is a risk factor for cardiovascular disease
in men. This belief was based on the observation that
men have both a higher incidence of cardiovascular
events and higher testosterone levels than women of
similar ages. However, few, if any, recent observa-
tions support a causal relation between higher testos-
terone levels and heart disease (1–3). On the
contrary, several studies suggest that higher testoster-
one levels are associated with a more favourable risk
effect on the risk of cardiovascular disease (4,5).
Studies of testosterone therapy have not demon-
strated an increased incidence of cardiovascular dis-
ease or events such as myocardial infarction, stroke
or angina (6,7). Evidence that testosterone therapy
may be beneﬁcial for men with cardiac disease is
becoming stronger (8,9).
This paper will analyse the interrelationship
between the metabolic syndrome, diabetes mellitus,
cardiovascular disease, (visceral) obesity, erectile
dysfunction (ED) and hypogonadism in (ageing)
men. Until recently, they were viewed as more or
less independent entities befalling the ageing male,
if necessary, treated by various medical specialties.
With a more integrative approach to the health
situation of middle-aged and elderly men, these
conditions appear closely interrelated in their
manifestations, hypothetically in their aetiology,
diagnostic strategy and also their treatment. This
paper takes the position that (improving) sexual
health is a portal to identify health hazards and
improving men’s health. Appropriate diagnosis and
medical work up of men presenting with sexual
symptoms may have the beneﬁt of the diagnosing
and treating other important conditions, such as
obesity, diabetes, hypertension and hyperlipida-
emia.
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SUMMARY
Aim: To identify the relationship of erectile dysfunction, hypogonadism and the
metabolic syndrome in the context of men’s health. Methods: An Expert Panel
Meeting was held in December 2006 in Vienna, Austria. In addition a comprehen-
sive literature search was conducted. Results: Men have a higher incidence of car-
diovascular events than women of similar ages which has led to the belief that
testosterone is a risk factor for cardiovascular disease in men. The latter hypothesis
is no longer tenable. On the contrary, low testosterone levels are associated with
(visceral) obesity, the metabolic syndrome, diabetes mellitus, cardiovascular disease
and erectile dysfunction (ED). Testosterone therapy does not lead to an increased
incidence of cardiovascular disease or events such as myocardial infarction, stroke
or angina. Until recently (visceral) obesity, the metabolic syndrome, diabetes mell-
itus, cardiovascular disease and ED were viewed as more or less independent enti-
ties affecting the ageing male. It was not recognised that hypogonadism is a
common denominator. With a more integrative approach to the health situation of
middle-aged and elderly men, these conditions appear closely interrelated in their
manifestations, hypothetically in their aetiology, diagnostic strategy and also their
treatment. Conclusion: Improving sexual health is a portal to identify health haz-
ards and improving men’s health. Appropriate diagnosis and medical work up of men
presenting with sexual symptoms may have the beneﬁt of the diagnosing and treating
other important conditions, such as obesity, diabetes, hypertension and hyperlipida-
emia.
Review Criteria
The original premise for this review arose from an
Expert Panel Meeting held in December 2006 in
Vienna, Austria and sponsored by Bayer-Schering
AG, Berlin, Germany. The panel discussed whether
the low testosterone levels found in men with the
metabolic syndrome are an essential element of the
syndrome. Further, it was discussed that sexual
dysfunction in middle-aged and elderly men should
be viewed in the context of their general health.
Message for the Clinic
When middle-aged and elderly men seek medical
advice for sexual dysfunction, their complaints should
no longer be viewed as a single diagnostic ⁄
therapeutic entity. Sexual dysfunction is usually an
expression of impairment of general health, not
rarely the metabolic syndrome. Diagnosis and
treatment should include assessment of the
components of the metabolic syndrome, which are
(visceral) obesity, hypertension, insulin resistance and
diabetes mellitus and dyslipidaemia. Thus sexual
dysfunction should be a portal to men’s health.
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cardiovascular disease and diabetes:
the metabolic syndrome
Obesity is a condition that is reaching epidemic
proportions in both the developed and the devel-
oping world (10). A preferential accumulation of
intra-abdominal fat is associated with hyperten-
sion, dyslipidaemia [elevated levels of cholesterol,
of triglycerides, of low-density lipoproteins (LDLs)
and low levels of high-density lipoproteins
(HDLs)], impaired glucose tolerance with hyperin-
sulinaemia, a cluster known as the ‘metabolic syn-
drome’ (11–13) (Table 1). There is a debate in
the literature whether combining these components
or conditions has an added diagnostic or prognos-
tic value. Meanwhile, there are three main deﬁni-
tions of the metabolic syndrome. These deﬁnitions
overlap but differ in the points of emphasis of
the components (14–16). The metabolic syndrome
is not an end disease by itself but its rather a
pathway to disease. A clinical investigation analy-
sing 11 prospective European cohort studies of
6156 men with a median follow-up of 8.6 years
found that non-diabetic persons with the meta-
bolic syndrome had increased risk of death of all
causes as well as cardiovascular disease (17). The
West of Scotland Coronary Prevention Study fol-
lowed 6000 men for periods over 5 years and
found that men with four or ﬁve features of the
metabolic syndrome had a 3.7-fold increases in
coronary heart disease events and, even more
strikingly, a 24.5-fold increase in new-onset diabe-
tes (18).
Epidemiological studies linking risk
factors of cardiovascular disease to
low testosterone levels
Initially cross-sectional studies but later also longitu-
dinal studies were able to conﬁrm that low testoster-
one levels and sex hormone-binding globulin
(SHBG) were predictive of the metabolic syndrome,
not only in obese men but also in men with a body
mass index (BMI) < 25 kg⁄m
2 (19–21). The same
applied to the risks of developing diabetes mellitus
type 2 (22–24). The association between low testos-
terone⁄low SHBG levels and the metabolic syndrome
is beyond any reasonable doubt now. The cause and
effect relation remains, however, a subject of further
study. The following will examine the relationship
between testosterone on the one hand and the
metabolic syndrome in greater detail. It is becoming
clear that the relationship is in fact a two way street:
low levels of testosterone predispose to (visceral)
adiposity and (visceral) adiposity suppresses the
production of testosterone.
The relationship between
hypogonadism and insulin resistance
and diabetes mellitus
Cross-sectional epidemiological studies have reported
a direct correlation between plasma testosterone and
insulin sensitivity, and low testosterone levels are
associated with an increased risk of type 2 diabetes
mellitus in men (21,24–26), for review: (27,28). A
study in untreated hypogonadal Klinefelter patients
using the hyperinsulinaemic euglycaemic clamp tech-
nique found hyperinsulinaemia and insulin resistance
in these patients (29).
Table 1 Deﬁnitions of the metabolic syndrome
At least two of
IDF WHO* NCEP
BMI ‡ 0.30 ‡ 30
Waist circumference (cm) ‡ 94 > 102 ‡ 94
Waist hip ratio > 0.90 > 0.90
At least two of
Triglycerides (mg⁄dl) ‡ 150 ‡ 150 ‡ 150
HDL-cholesterol (mg⁄dl) < 35 < 40 < 35
Blood pressure (mmHg) ‡ 140⁄90 or medication ‡ 130⁄85 or medication ‡ 140⁄90 or medication
Fasting glucose (mg⁄dl) ‡ 110 ‡ 110
Fasting insulin Upper quartile of non-diabetic Insulin resistance
*World Health Organization, Diabetes Med 1999; 16: 442–3. National Cholesterol Education Program, JAMA 2001; 285: 2486–97.
International Diabetes, J Urol 2005; 174: 827–34. BMI, body mass index; HDL, high-density lipoprotein.
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between serum testosterone levels and insulin sensi-
tivity in men across the full spectrum of glucose tol-
erance (30). In this study, men with hypogonadal
testosterone levels were twice as insulin resistant as
their eugonadal counterparts, and 90% fulﬁlled crite-
ria for the metabolic syndrome.
The suppressive effect of adipose
tissue on the synthesis of testosterone
The adipocyte functions as an endocrine cell, pro-
ducing and secreting adipocytokines⁄adipokines of
which leptin is a prominent member. Leptin recep-
tors are present on the Leydig cell and inhibit the
testosterone generated by administration of human
chorionic gonadotropin (31,32). This ﬁnding was
supported by studies that found a negative correla-
tion between adiposity, insulin and leptin on the one
hand and testosterone levels on the other (33,34).
Hyperinsulinaemia as encountered in insulin resis-
tance might impair testosterone secretion by the
Leydig cell, maybe directly as there are insulin recep-
tors on the Leydig cell (35). Conversely, in an elegant
study (35). Insulin resistance impairs basal and
human chorionic gonadotropin (hCG)-stimulated
testosterone secretion from the Leydig cell. Overcom-
ing the hyperglycaemia with the hyperinsulinaemic
euglycaemic clamp technique led to a rise of plasma
testosterone. This study showed an effect of testoster-
one on insulin sensitivity within 48 h, so this was
not an indirect effect mediated through changes in
body composition.
It has also been found in obese men that that
there is an attenuated pulse amplitude of luteinizing
hormone (LH) while the LH pulse frequency is unaf-
fected, thus producing a less strong stimulation of
testicular testosterone production (36,37).
Metabolic effects of (rather) acute
androgen deprivation in men with
prostate cancer
Prostate cancer is an androgen-dependent malig-
nancy and, consequently, androgen deprivation treat-
ment (ADT) has a role to play in its management
(38). Several studies have documented the deteriora-
tion of metabolic control upon ADT (39–49) in dia-
betic and non-diabetic men. Collectively, these
studies have found that ADT leads to an increase in
fat mass, an increase in plasma insulin, decreased
insulin sensitivity (48), increased levels of glycosylat-
ed haemoglobin, an increase in plasma cholesterol,
LDL-cholesterol and triglycerides but also an increase
in plasma HDL-cholesterol, which contrasts with the
low HDL-cholesterol levels found in the metabolic
syndrome.
A recent study analysed the effects of GnRH ago-
nist administration to men with prostate cancer;
73,196 Medicare patients ‡ 66 years who had locore-
gional prostate cancer between 1992 and 1999 were
followed through 2001. The study assessed whether
treatment with GnRH agonists or was associated
with diabetes, coronary heart disease, myocardial
infarction and sudden cardiac death. GnRH agonist
therapy was associated with increased risk of incident
diabetes [adjusted hazard ratio (HR), 1.44;
p < 0.001], coronary heart disease (adjusted HR,
1.16; p < 0.001), myocardial infarction (adjusted HR,
1.11; p = 0.03) and sudden cardiac death (adjusted
HR, 1.16; p = 0.004). Therefore, GnRH agonist treat-
ment should be weighed against these potential risks
(44).
At the cellular levels there is now insight into the
effects of androgen deprivation⁄administration on fat
mass. Testosterone regulates lineage determination in
mesenchymal pluripotent cells by promoting their
commitment to the myogenic lineage and inhibiting
their differentiation into the adipogenic lineage
through an androgen receptor-mediated pathway.
The observation that differentiation of pluripotent
cells is androgen dependent provides a unifying
explanation for the reciprocal effects of androgens on
muscle and fat mass in men (50,51).
Prostate cancer patients treated with ADT need to
be monitored with reference to possible metabolic
consequences of ADT. The survival of patients with
prostate cancer has improved considerably. Cause of
death in prostate cancer patients is no longer mainly
because of the malignancy but to other conditions
(52). Therefore, it has become increasingly important
to address side effects of treatment timely and appro-
priately (53).
Testosterone in men with diabetes
mellitus type 2
Similar to studies in men with the metabolic syn-
drome, there is an inverse relationship between tes-
tosterone levels and diabetes. This relationship has
been established and conﬁrmed since the mid-1980s.
A recent study reported not only low levels of testos-
terone but also symptoms thereof in men with diabe-
tes stressing the clinical relevance of the association
(54). Men with diabetes have lower testosterone lev-
els compared with men without a history of diabetes,
even without adiposity (24).
A recent systematic review and meta-analysis of
cross-sectional studies indicated that testosterone
level was signiﬁcantly lower in men with type 2
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dence interval (CI), )99.4 to )53.6]. Similarly, pro-
spective studies showed that men with higher
testosterone levels (range: 449.6–605.2 ng⁄dl) had a
42% lower risk of type 2 diabetes (relative risk, 0.58;
95% CI: 0.39–0.87). In addition, several large pro-
spective studies have shown that low testosterone
levels predict development of type 2 diabetes in men
(22,23,55).
A recent study analysing the effects of testosterone
administration to 24 hypogondal men (10 treated
with insulin) over the age of 30 years with type 2
diabetes found that testosterone replacement therapy
reduced insulin resistance (as measured by homeo-
static model index) and improved glycaemic control
in hypogonadal men with type 2 diabetes (56). There
are indications now that the beneﬁcial effects of tes-
tosterone on the metabolic syndrome are related to
their impact on body composition and this effect will
only occur in the longer-term (57,58) 6–12 months
of testosterone administration. This might explain
why shorter term studies (3 months) do not show
many favourable effects (56).
New insights into the relationship
of androgens and erectile dysfunction
Erectile response in mammals is centrally and
peripherally regulated by androgens. Severe hypog-
onadism in men usually results in loss of libido and
potency which can be restored by androgen adminis-
tration. The original insights into the mechanisms of
action of androgens on sexual function indicated a
prominent role of testosterone on sexual interest
while the effects of testosterone on erectile function
were less apparent from these investigations (59).
There is growing insight that testosterone has pro-
found effects on tissues of the penis involved in the
mechanism of erection and that testosterone
deﬁciency impairs the anatomical and physiologi-
cal⁄biochemical substrate of erectile capacity, revers-
ible upon androgen treatment. An improvement of
nocturnal erections [tumescence and rigidity, sponta-
neous and sexually related erections was found in
men with androgen deﬁciency upon treatment with
transdermal testosterone (60) and eugonadal circum-
stances].
Several studies have indicated that the administra-
tion of phosphodiesterase inhibitor type-5 (PDE-5)
inhibitors is not always sufﬁcient to restore erectile
potency in men, and that administration of testoster-
one improves the therapeutical response to PDE-5
inhibitors considerably (61,62). There is increasing
insight not to view ED as a single entity but as part
of the ageing process. Circulating levels of testoster-
one are closely related to manifestations of other
aetiological factors in ED, such as atherosclerotic dis-
ease and diabetes mellitus. The latter are correlated
with lower-than-normal testosterone levels.
Erectile difﬁculties provide often a window into
the presence of pathology in these areas. Rather than
a disease in itself, ED is, particularly in elderly men
who have enjoyed normal sexual function earlier in
life, a manifestation of pathologies of the biological
systems involved in erectile function (63).
Animal experiments and, to a much more limited
degree, human observations suggest that androgens
are necessary to maintain the integrity of the ana-
tomical structures of the penile erectile tissue and,
further, that androgens are signiﬁcant in the bio-
chemical mechanisms subserving penile erection.
There is now ample evidence from animal studies
that androgen deprivation produces changes in the
histological properties of penile structures. Shabsigh
(64) could demonstrate that castration caused apop-
tosis in the rat corpus cavernosum smooth muscle
after only 3 days. Administration of testosterone
restored DNA synthesis already after 4 days. In a rat
model Shen et al. [reviewed in (65)] demonstrated
that androgen deprivation leads to loss of elastic
ﬁbres in the tunica albuginea and of smooth muscle
ﬁbres in the corpus cavernosum [reviewed in (65)]
which were replaced by collagenous ﬁbres in both
structures. Singh et al. [reviewed in (65)] found that
the mesenchymal pluripotent cells follow a myogenic
lineage or adipogenic lineage depending on circulat-
ing levels of testosterone, conﬁrmed by Traish et al.
[reviewed in (65)].
Traish and coworkers [reviewed in (65)] demon-
strated that even a 50% reduction in circulating tes-
tosterone reduced intracavernosal blood pressure
which was not enhanced by administration of the
PDE-5 inhibitor vardenaﬁl. Zhang et al. (66) showed
that also continuous administration of tadalaﬁl could
not enhance erectile response in castrated animals.
Nitric oxide synthase and arginase activities in the
corpus cavernosum were not signiﬁcantly affected by
the reduction in circulating testosterone conﬁrmed
in human tissue by Morelli et al. (67). Yassin and
Saad (68) showed that adequate testosterone treat-
ment can restore venous leakage in the corpus
cavernosum which is a frequent etiological factor in
ED in elderly men.
Schiavi and Rehman (69), based on their clinical
experience, hypothesised that the threshold for the
biological actions of testosterone might be higher in
elderly men compared with young men. Their
hypothesis was recently convincingly experimentally
conﬁrmed by Gray et al. (70) showing that, com-
pared with younger men, elderly men require higher
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tile function.
Erectile dysfunction is a ‘portal’
to men’s health
The above has demonstrated a close relationship
between ailments frequently occurring in the ageing
male (visceral obesity, cardiovascular disease, diabetes
mellitus and ED) on the one hand and hypogona-
dism on the other. In view of this close relationship,
late onset hypogonadism is probably an expression
of poor health with a high-risk proﬁle for debilitat-
ing diseases, as may be concluded from a recent
study. Low testosterone levels were associated with
increased mortality in male veterans (71). This asso-
ciation between sex steroids and all-cause and cause-
speciﬁc mortality could not be conﬁrmed in Massa-
chusetts Male Aging Study (72).
Men usually are in denial of ailments at all ages,
but certainly also when they are ageing. Erectile func-
tion is viewed by almost all men as a signiﬁcant
component of quality of life (73) and erectile difﬁ-
culties (ED) may be a reason to seek medical advice.
Several studies document now that there is a high
concordance between the causes of ED and the
causes of cardiovascular disease, this indirectly by
demonstrating that there is an elevated prevalence of
the metabolic syndrome and insulin resistance in a
population of men with ED when compared with a
general population of men (74). The authors argue
that the ultimate goal therefore must be not only to
treat the erectile problem but also to diagnose and
adequately (aggressively) treat any cardiac risk factors
that may be found.
The prestigious Massachusetts Male Aging Study
equally revealed that ED was predictive of the meta-
bolic syndrome, although only in men with BMI
< 25. This ﬁnding also supports the notion that
waist circumference or waist⁄hip ratio are more reli-
able indicators of the metabolic syndrome that BMI.
This study supports the idea that ED may provide a
warning sign and, at the same time, an opportunity
for early intervention in men otherwise considered at
lower risk for the metabolic syndrome and subse-
quent cardiovascular disease (75). The Massachusetts
Male Aging Study (MMAS) has estimated the fre-
quency of ED progression and remission among age-
ing men, and assessed the relation of
progression⁄remission to demographics, socioeco-
nomic factors, comorbidities and modiﬁable lifestyle
characteristics. Natural remission and progression
occur in a substantial number of men with ED. Age
and BMI were associated with progression and
remission of ED. Interventions were non-pharmaco-
logical which apparently impacted on remission and
delaying progression of ED. The association of BMI
with remission and progression, and the association
of smoking and health status with progression, offer
potential avenues for facilitating remission and delay-
ing progression using non-pharmacological interven-
tion. The beneﬁts of such interventions for overall
men’s health may be far reaching and support the
view that sexual health is a portal to men’s health
(76). Lifestyle changes are associated with improve-
ment in sexual function in about one-third of obese
men with ED at baseline. Weight loss and increased
physical activity, and lower caloric intake, with a
Mediterranean type of diet, appeared to have a
favourable effect on erectile and endothelial functions
in obese men (77,78). It is recommendable that these
lifestyle changes are continued lifelong.
Shabsigh et al. (79) have eloquently argued that
ED can calculate men’s health risks (Table 2). The
men’s health calculator is intended to raise awareness
about cardiovascular disease and diabetes risk. It is
intended to be easy, short, quick and suitable for
both print and internet. The four questions address
different aspects of body functions and health. These
questions were derived from the Men’s Attitudes to
Life Events and Sexuality (MALES) study that
included a large number of subjects in eight coun-
tries. The questions function with their linguistic face
meaning without further explanation. The ﬁrst ques-
tion is self-rating of perceived state of health. The
second question is inquiring about having severe ED.
Table 2 Erectile dysfunction (ED) can calculate men’s
health risks: the MALES study
Variable Answer Values Score
Health status 0.5
Severe ED 1
Sexual partner )1.5
Waist size: 86–91 cm 1
Waist size: 96–101 cm 2
Waist size over 106 cm 2
Total
Y = f (health status, waist size, ED severity and sexual partner)
where Y = 0, 1 (no disease⁄disease). 90% sample = 349.
10% holdout sample = 40.
Risk for hypertension, diabetes, angina or hyperlipidaemia.
Score ranges from 0 to 7.
‡ 2.5 = high risk (‡ 60% probability of having the condition).
1.5–2.5 = medium risk (30–59% probability).
< 1.5 = low risk (< 30% probability).
Score of our patient: 3 = high risk.
If he had not had ED: 2 = medium risk.
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gate for vascular health. The third question is about
having a good relationship with the partner. This
could be hypothesised to be surrogate for mental
and behavioural health. The fourth question is about
waist circumference, which can be hypothesised to be
a surrogate for metabolic health. Elements in the cal-
culation of health risks (hypertension, diabetes,
angina or hyperlipidaemia) in men presenting with
ED are: health status on a scale of 1–7 (1 = excellent,
7 = poor), waist circumference, severity of ED, pres-
ence⁄absence of a sexual partner. The calculation
produces scores of ranges of 1–7. If the score is
1.5–2.5 = medium risk (30–59% probability);
‡ 2.5 = high risk (‡ 60% probability of having the
condition) and < 1.5 = low risk (< 30% probability).
Conclusions
Sexual health may be the portal to men’s health.
Lifestyle changes involving more exercise and a lower
caloric intake, with a Mediterranean type of diet,
appear to improve sexual function (77,78). It is rec-
ommendable that these measures are lifelong.
Hypogonadism and ED are epidemiologically asso-
ciated with and may predict metabolic syndrome and
diabetes type 2. However, there are signiﬁcant limita-
tions and knowledge gaps. Most evidence of the link
of hypogonadism and metabolic syndrome is obser-
vational. Interventional studies are needed to deter-
mine the relationship between testosterone and
diabetes mellitus and the metabolic syndrome to
assess the beneﬁt⁄risk ratio of testosterone replace-
ment therapy in men with the hypogonadism, diabe-
tes and the metabolic syndrome. Treatment of ED
may entail testosterone administration (80) and these
interventional studies may provide an opportunity to
determine therapeutic and preventive feasibility, ben-
eﬁts and justiﬁcation of testosterone administration
on the closely interrelated ailments of ED and the
metabolic syndrome of which epidemiologically hyp-
ogonadism is a correlate.
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